Maxim Norkin, MD
Hematology · Jacksonville, FLNPI 1841428588
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,092 of the $40,078 with a category attached, or 85.1%. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 58.1% of the total. Reporting peaked in 2024 at $14,902 and has fallen 56.4% since, to $6,491 in 2025.
Across 57 payments — averaging $703.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$23K
- Novartis$6K
- Incyte Corporation$3K
- Bristol Myers Squibb$3K
- CTI Biopharma Corp.$2K
- Beigene, Ltd.$1K
- plus $2K from 8 others
Across 284 payments — averaging $5547.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$537K
- Novartis$265K
- ADC Therapeutics America, Inc.$235K
- Genentech, Inc.$170K
- Bristol Myers Squibb$113K
- Otsuka Pharmaceutical Co., Ltd.$99K
- plus $157K from 7 others
What the payments were for
- Consulting fees$34,09285%
- Speaking & faculty fees$2,7007%
- Travel & lodging$1,8425%
- Food & beverage$1,3103%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 16 | $23,298 |
| Novartis | 3 | $6,225 |
| Incyte Corporation | 1 | $3,300 |
| Bristol Myers Squibb | 13 | $2,811 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Beigene, Ltd. | 2 | $1,000 |
| AstraZeneca | 3 | $550 |
| GSK | 1 | $430 |
| Sanofi | 2 | $425 |
| Beigene USA, Inc. | 11 | $119 |
| Astellas Pharma US Inc | 1 | $95 |
| Genentech, Inc. | 1 | $40 |
| Gilead | 1 | $38 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,078 in reported general payments places this provider in the 80th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 115 | $2,670,912 |
| RevlimidLenalidomide | 133 | $2,556,697 |
| BrukinsaZanubrutinib | 129 | $1,894,827 |
| CalquenceAcalabrutinib Maleate | 67 | $970,273 |
| Lenalidomide | 63 | $948,072 |
| VenclextaVenetoclax | 73 | $627,629 |
| ScemblixAsciminib Hydrochloride | 24 | $546,208 |
| ImbruvicaIbrutinib | 30 | $512,242 |
| JaypircaPirtobrutinib | 20 | $509,333 |
| SprycelDasatinib | 32 | $466,374 |
| VyndamaxTafamidis | 19 | $465,506 |
| JakafiRuxolitinib Phosphate | 29 | $449,804 |
| BosulifBosutinib | 13 | $378,566 |
| GleevecImatinib Mesylate | 16 | $159,009 |
| PromactaEltrombopag Olamine | 14 | $118,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $23,298 | $3,137,285147 claims |
| Bristol Myers SquibbRevlimid | $2,811 | $2,556,697133 claims |
| Beigene USA, Inc.Brukinsa | $119 | $1,894,827129 claims |
| AstraZenecaCalquence | $550 | $970,27367 claims |
| NovartisScemblix, Gleevec, Promacta | $6,225 | $823,52554 claims |
| Incyte CorporationJakafi | $3,300 | $449,80429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 hematology providers in Florida.
Other hematology in Jacksonville
- Mohamed Kharfan DabajaJacksonville$32K
- Yiyi YanJacksonville$2K
- Yenny Moreno VanegasJacksonville$922
- Zaid Abdel RahmanJacksonville$715
- Razan MohtyJacksonville$592
- Ernesto AyalaJacksonville$241
- Mehmet UyanikJacksonville$147
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.